Similarly to BRCA1-mutated ovarian cancer cells, HRDhigh sarcoma cells showed higher sensitivity than HRDlow sarcoma cells to PARPi but no major differential response to chemotherapy (Fig. 2a). This evidence concerns the gene BRCA1 and ovarian carcinoma.